Dr. Madigan has a strong scientific background and 30 years of experience in corporate financing, operations, business and corporate development, and M&A. Dr. Madigan is a Managing Partner with Avalon BioVentures and previously was a serial entrepreneur for Avalon Ventures portfolio companies. Most recently, in Avalon XI, Dr. Madigan was co-founder and CEO of Nerio Therapeutics (acquired by Boehringer-Ingelheim in July, 2024 for up to $1.3B). Previously, in Avalon X, Dr. Madigan was the transacting CEO of Calporta Therapeutics (acquired by Merck in November, 2019 for up to $576M).

Dr. Madigan was also a founding member of various Avalon Ventures portfolio companies from earlier funds, including Ambit Biosciences (IPO, acquired by Daiichi Sankyo), Xenopharm (acquired by Deltagen) and X-Ceptor Therapeutics (acquired by Exelixis).

Outside of the Avalon portfolio, he was a founder and the CEO of Strategic Enzyme Applications, a private company established in partnership with Monsanto. Dr. Madigan was also a founder and VP Corporate Development for BioVerdant, a venture-backed clean technology company.

Dr. Madigan performed his post-doctoral training at The Salk Institute for Biological Studies. He received his Ph.D. in Genetics and his B.S. in Biochemistry from The State University of New York at Stony Brook where, as a graduate student, he was awarded the Abrahams Memorial Award for outstanding potential for basic research.